Fig. 2

Simultaneous assessment of MGMT and IDH status in 4 IDH-mutant clinical samples. a, Methylation was assayed by pyrosequencing and nCATS in 2 DNA standards: CpG methylated (MetCtrl) and unmethylated (UnMetCtrl). b, Methylation was assayed in DNA extracted from 4 glioblastoma cell lines: U87, U251, T98G, and LN18. Correlation (r) of methylation level between nCATS and pyrosequencing was calculated with P-value. Each yellow point is an individual CpG. c, Methylation pattern was assayed by pyrosequencing, MassARRAY, and nCATS in 4 IDH-mutant clinical samples. Correlation (r) of methylation level between nCATS and pyrosequencing was calculated with P-value. Each yellow point is an individual CpG. d,IDH mutations were detected with the nCATS, Illumina, and Sanger sequencing platforms. IDH1 mutations were accurately detected in 3 patients (blue rows), and IDH2 mutation was detected in 1 patient (orange row). The pie charts and percentages indicate allele frequency detected by each method